Sorafenib for Egyptian patients with advanced hepatocellular carcinoma; single center experience
Conclusions In limited resource countries like Egypt, we suggest that the use of sorafenib for the treatment of advanced HCC cases should be restricted to a highly selected subgroup of patients with good performance and child A.
Source: Journal of the Egyptian National Cancer Institute - Category: Cancer & Oncology Source Type: research
More News: Cancer | Cancer & Oncology | Carcinoma | Children | Egypt Health | Hepatocellular Carcinoma | Liver | Liver Cancer | Liver Disease | Study | Urology & Nephrology